CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire

 
• By Derrick Gingery
  
backfire
Stakeholders likely will closely watch the upcoming FDA advisory committee meeting on Sarepta's DMD gene therapy candidate. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies